Overview

This trial is active, not recruiting.

Condition capsular contractures
Treatment trental
Sponsor Legacy Health System
Start date October 2009
End date August 2013
Trial size 30 participants
Trial identifier NCT01082003, LHS T-E01

Summary

The main purpose of this research study is to determine if the use of Trental and Vitamin E will decrease the incidence and severity of contractures (shrinking and or hardening of tissue surrounding the implant) associated with breast implant reconstruction following radiation treatment. Another goal is to find out the impact that Trental and Vitamin E have on implant loss or need for surgical intervention in the setting of chest wall radiation after reconstruction. In addition, the investigators want to evaluate the patient's sense of well being and quality of life.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose prevention
Arm
(Other)
Trental and Vitamin E for 6 months
trental
Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
(Other)
Trental and Vitamin E for 6 months
trental
Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.

Primary Outcomes

Measure
Measure number and grade of contractures occurring after implant reconstruction and radiation treatment in subjects receiving Trental and vitamin E combination compared to placebo using the Bakers grade assessment
time frame: 6 months

Secondary Outcomes

Measure
Number of implant revisions or loss of implants due to post radiation changes in subject receiving Trental and vitamin E compared to placebo through patient interview with research staff
time frame: 6 months

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Female subjects - > 18 years of age - Expected survival at least > 6 months - Undergone mastectomy with expander or implant reconstruction > 3 weeks before radiation therapy - Completed chest wall irradiation in the past two weeks - Willing to stop herbal medications as directed by physician - Willing to stop daily use of supplemental vitamin E (Multivitamin with vitamin E component is acceptable) - Willing to travel to a Legacy Health System facility - Agree to attend study visits outside of standard of care visits - Normal PT-INR for subjects taking Coumadin Exclusion Criteria: - < 18 years of age - Pregnant or lactating - Have final implant placed < 3 weeks before start of radiation therapy - Have evidence of ongoing infection or implant exposure before start of radiation therapy - Radiation completed more than 16 days prior to study start - Retinitis Pigmentosa - Unable to comply with protocol - Unable to provide written informed consent - Unwilling or unable to stop supplemental vitamin E - PT-INR outside of acceptable range for subjects taking Coumadin - Investigator does not believe study participation, for any reason is in the best interest of the patient

Additional Information

Official title A Single Center, Prospective Treatment Trial to Assess Prophylactic Use of Trental (Pentoxifylline) and Vitamin E to Prevent Capsular Contracture After Implant Reconstruction in Patients Requiring Adjuvant Radiation Therapy
Principal investigator Nathalie Johnson, MD
Description This is a single center, 18-month study in which 30 women will receive Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months. Subjects will begin the treatment regimen within four weeks after completion of radiation treatment and will remain on the study drugs for six months. Following completion of active treatment, all subjects will enter the twelve-month observational phase of the trial in which they will be evaluated for changes in breast tissue using the following objective tools: Bakers Grade Assessment, Visual Analog Scale (VAS), implant revision or loss, breast photographs, adverse event assessment and the Quality of Life tool (SF-12).
Trial information was received from ClinicalTrials.gov and was last updated in August 2013.
Information provided to ClinicalTrials.gov by Legacy Health System.